Read twice and referred to the Committee on Finance.
The bill requires the Center for Medicare and Medicaid Innovation (CMMI) to test a payment model that allows blood transfusions for Medicare hospice patients to be paid separately from the hospice all-inclusive per diem. CMMI must implement the model within one year of enactment; separate payment equals the Medicare amount that would apply if transfusion were not provided under hospice.
Progressives emphasize expanded patient access and symptom relief.
Relative to its intended legislative type, this bill clearly and narrowly mandates that the Center for Medicare and Medicaid Innovation implement and evaluate a demonstration testing separate payment for blood transfusions furnished to hospice patients, and it integrates that mandate into existing model-selection authority while specifying payment amount and evaluation metrics.
The bill requires the Center for Medicare and Medicaid Innovation (CMMI) to test a payment model that allows blood transfusions for Medicare hospice patients to be paid separately from the hospice all-inclusive per diem.
CMMI must implement the model within one year of enactment; separate payment equals the Medicare amount that would apply if transfusion were not provided under hospice.
The model must be evaluated against specified metrics (hospital use near end of life, hospice days, transfusion frequency, and similar measures).
Limited, administratively focused change with clear evaluation metrics improves prospects, though cost concerns and competing priorities create uncertainty.
Relative to its intended legislative type, this bill clearly and narrowly mandates that the Center for Medicare and Medicaid Innovation implement and evaluate a demonstration testing separate payment for blood transfusions furnished to hospice patients, and it integrates that mandate into existing model-selection authority while specifying payment amount and evaluation metrics. The statutory insertion is direct and actionable at a high level.
Progressives emphasize expanded patient access and symptom relief.
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize expanded patient access and symptom relief.
Likely supportive because the bill addresses an access barrier for hospice patients needing transfusions.
It frames the change as a limited, evidence-driven CMMI test rather than a permanent payment expansion.
Cautiously favorable: supports testing through CMMI, but wants clear evaluation design, cost controls, and guardrails to preserve hospice goals.
Will weigh evidence before supporting broader rollout.
Skeptical: appreciates a limited CMMI test but worries it may expand federal payments and encourage more aggressive care in hospice.
Prefers strict fiscal and philosophical safeguards.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Limited, administratively focused change with clear evaluation metrics improves prospects, though cost concerns and competing priorities create uncertainty.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize expanded patient access and symptom relief.
Limited, administratively focused change with clear evaluation metrics improves prospects, though cost concerns and competing priorities cr…
Relative to its intended legislative type, this bill clearly and narrowly mandates that the Center for Medicare and Medicaid Innovation implement and evaluate a demonstration testing separate payment for blood transfusi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.